Under our 2014 Incentive Plan (“2014 Plan”), as amended, the Company is authorized to grant awards in the form of incentive stock options, non-qualified stock options, restricted stock shares, restricted stock units, other common stock-based awards and cash-based awards. As of December 31, 2024, the Company had reserved 15.1 million shares of common stock for the grant of awards under the 2014 Plan, subject to adjustment as provided by the 2014 Plan. All shares under the Plan may be made subject to options, stock appreciation rights (“SARs”), or stock-based awards. Stock options and SARs granted under the 2014 Plan may not have a term exceeding 10 years from the date of grant. The 2014 Plan also provides that all awards will become fully vested and/or exercisable upon a change in control (as defined in the 2014 Plan) if those awards (i) are not assumed or equitably substituted by the surviving entity or (ii) have been assumed or equitably substituted by the surviving entity, and the grantee’s employment is terminated under certain circumstances. Other specific terms for awards granted under the 2014 Plan shall be determined by our Compensation Committee (or the board of directors if so determined by the board of directors). Awards granted under the 2014 Plan generally vest ratably over a three to four-year period or cliff vest after a period of three to four years. As of December 31, 2024, 7.6 million shares were available for issuance under the 2014 Plan. If it is assumed that shares will be issued at the target vesting amount for outstanding RSUs with variable payout provisions, an additional 0.4 million shares would be included in the shares available for future issuance under the 2014 Plan.

We were authorized to issue shares of common stock pursuant to awards granted in various forms under our 1998 Stock Incentive Plan, 2005 Equity Incentive Plan, and 2007 Incentive Plan. No further grants will be made under these plans and all remaining awards granted under these plans are fully vested and exercisable.

The following table summarizes our stock option activity:


				Weighted		Weighted
				Average		Average
				Exercise		Remaining		Aggregate
	Options			Price		Years		Intrinsic Value
	(in thousands)							(in thousands)
Outstanding at December 31, 2023		57		$	9.88
Exercised		(32	)		8.87
Forfeited		—			—
Outstanding at December 31, 2024		25			11.17		1.0	$	3,303
Exercisable at December 31, 2024	$	25		$	11.17		1.0	$	3,303

The outstanding options at December 31, 2024, are options granted under the 2014 plan and are exercisable. There were no outstanding options at December 31, 2024, under the 2007 Plan, the 2005 Plan, and the 1998 Plan. There were no options granted and no options vested during the years ended December 31, 2024, 2023 or 2022. The total intrinsic value of options exercised during the years ended December 31, 2024, 2023 and 2022 were $5.4 million, $9.0 million and $3.6 million, respectively.

The total outstanding RSUs at December 31, 2024, include 1.0 million units granted under the 2014 Plan.

The Company grants RSUs to employees under our 2014 Incentive Plan for which vesting is based solely on continuous employment over the requisite service period. The following table summarizes activity for RSUs subject solely to service conditions for the year ended December 31, 2024:


				Weighted
				Average Grant
	Shares			Date Fair Value
	(in thousands)
Nonvested at December 31, 2023		1,118		$	68.35
Granted		280			186.61
Vested		(716	)		62.46
Forfeited		(46	)		105.95
Nonvested at December 31, 2024		636		$	124.37

The weighted average grant date fair value of RSUs for which vesting is subject solely to service conditions granted during the years ended December 31, 2024, 2023 and 2022 was $186.61, $87.05, and $62.46, respectively.

The Company grants RSUs to employees under our 2014 Incentive Plan, that generally vest based on the Company’s level of achievement of performance goals relating to return on invested capital over a three-year period (“performance condition”) as well as continued employment during the performance period (“service condition”). The total number of shares of common stock that may be earned from the performance condition ranges from zero to 200% of the RSUs granted. The number of shares earned from the performance condition may be further increased or decreased by 10% based on the Company’s total shareholder return relative to a peer group during the performance period (“market condition”). The following table summarizes activity for these RSUs for the year ended December 31, 2024:


				Weighted
				Average Grant
	Shares			Date Fair Value
	(in thousands)
Nonvested at December 31, 2023		406		$	72.22
Granted		86			201.97
Performance & market achievement adjustment (1)		73			47.85
Vested		(185	)		47.85
Forfeited		(22	)		105.81
Nonvested at December 31, 2024		358		$	108.87

(1) Represents RSUs granted prior to 2024 for which the performance and market achievement period was completed in 2024, resulting in incremental unit awards granted. These incremental awards are also included in the amount vested in 2024.

The weighted average grant date fair value of RSUs for which vesting is subject to performance, market and service conditions granted during the years ended December 31, 2024, 2023 and 2022 was $201.97, $88.48 and $70.77, respectively.

Our results of operations include stock compensation expense of $63.1 million, $48.5 million and $31.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. We recognized excess tax benefits for stock options exercised and RSUs vested of $27.6 million, $16.3 million and $16.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. The total fair value of RSUs vested during the years ended December 31, 2024, 2023 and 2022 was $53.6 million, $37.6 million and $29.0 million, respectively.

As of December 31, 2024, there was $64.6 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plans. That cost is expected to be recognized over a weighted-average period of 1.9 years.